William H. Meyer

Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children

Wayne L. Furman, Clinton F. Stewart, Catherine A. Poquette et al. · Journal of Clinical Oncology · 1999 · 233 citations

Medicine, Oncology, Pharmacology +17

Human Rights and MNCs: Theory Versus Quantitative Analysis

William H. Meyer · Human Rights Quarterly · 1996 · 129 citations

Social Sciences, Development Studies, Development Economics +10

Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.

C B Pratt, A A Green, Marc E. Horowitz et al. · Journal of Clinical Oncology · 1986 · 128 citations

Medicine, Neurology, Oncology +17

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

Mary V. Relling, John W. Cherrie, Michael J. Schell et al. · Clinical Pharmacology & Therapeutics · 1991 · 103 citations

Veterinary Medicine, Genetics, Pharmacology +15

Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors

William C. Zamboni, Laura C. Bowman, Ming Tan et al. · Cancer Chemotherapy and Pharmacology · 1999 · 70 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +14